said its subsidiary hVivo has signed a deal with a major pharmaceutical client to manufacture a virus for use in human challenge studies.
Manufacturing has already begun, and the work is expected to be completed by the end of the third quarter.
Congrats Cathal.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: